NASDAQ:HALO - Halozyme Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $15.61 -0.31 (-1.95 %) (As of 05/20/2019 08:43 AM ET)Previous Close$15.92Today's Range$15.55 - $16.005052-Week Range$13.24 - $19.56Volume706,074 shsAverage Volume718,862 shsMarket Capitalization$2.27 billionP/E RatioN/ADividend YieldN/ABeta1.79 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Halozyme Therapeutics, Inc., a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. The company's products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its pipeline include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs in subcutaneous urography; and to enhance resorption of radiopaque agents. The company also develops PEGPH20, a therapy that is in Phase III clinical trial for pancreatic ductal adenocarcinoma; in Phase Ib clinical trial for non-small cell lung cancer; in Phase Ib/II clinical trial for patients with previously treated metastatic pancreatic ductal adenocarcinoma; in Phase Ib/II clinical trial for patients with gastric cancer; and in Phase Ib/II for cholangiocarcinoma and gall bladder cancer. It has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; and ARGENX BVBA. The company was founded in 1998 and is headquartered in San Diego, California. Receive HALO News and Ratings via Email Sign-up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:HALO Previous Symbol CUSIP40637H10 CIK1159036 Webwww.halozyme.com Phone858-794-8889Debt Debt-to-Equity Ratio0.07 Current Ratio2.95 Quick Ratio2.72Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$151.86 million Price / Sales14.96 Cash FlowN/A Price / Cash FlowN/A Book Value$1.79 per share Price / Book8.72Profitability EPS (Most Recent Fiscal Year)($0.56) Net Income$-80,330,000.00 Net Margins-28.70% Return on Equity-20.36% Return on Assets-11.42%Miscellaneous Employees281 Outstanding Shares145,510,000Market Cap$2.27 billion Next Earnings Date8/6/2019 (Estimated) OptionableOptionable Halozyme Therapeutics (NASDAQ:HALO) Frequently Asked Questions What is Halozyme Therapeutics' stock symbol? Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO." How were Halozyme Therapeutics' earnings last quarter? Halozyme Therapeutics, Inc. (NASDAQ:HALO) posted its quarterly earnings data on Tuesday, May, 7th. The biopharmaceutical company reported $0.01 earnings per share for the quarter, meeting the consensus estimate of $0.01. The biopharmaceutical company earned $56.95 million during the quarter, compared to analysts' expectations of $67.80 million. Halozyme Therapeutics had a negative return on equity of 20.36% and a negative net margin of 28.70%. Halozyme Therapeutics's revenue for the quarter was up 84.3% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.19) earnings per share. View Halozyme Therapeutics' Earnings History. When is Halozyme Therapeutics' next earnings date? Halozyme Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August 6th 2019. View Earnings Estimates for Halozyme Therapeutics. What guidance has Halozyme Therapeutics issued on next quarter's earnings? Halozyme Therapeutics issued an update on its FY 2019 earnings guidance on Tuesday, May, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $205-215 million, compared to the consensus revenue estimate of $209.09 million. What price target have analysts set for HALO? 4 Wall Street analysts have issued twelve-month price targets for Halozyme Therapeutics' stock. Their forecasts range from $17.00 to $24.00. On average, they anticipate Halozyme Therapeutics' stock price to reach $20.75 in the next year. This suggests a possible upside of 32.9% from the stock's current price. View Analyst Price Targets for Halozyme Therapeutics. What is the consensus analysts' recommendation for Halozyme Therapeutics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Halozyme Therapeutics. What are Wall Street analysts saying about Halozyme Therapeutics stock? Here are some recent quotes from research analysts about Halozyme Therapeutics stock: 1. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and $24 PT per share on HALO. Halozyme reported 1Q19 revenues of $57M, which were below our and FactSet consensus estimates of $62M and $69M, respectively. Additionally, the company ended 1Q19 with cash of ~$329M, and we model current cash and projected ENHANZE royalties to fund HALO through key value-creating milestones. During 1Q19, royalty revenues declined by 14% YoY, mainly due to lower sales of Herceptin SC in Europe, which were partially offset by higher sales of RITUXAN HYCELA versus 1Q18." (5/8/2019) 2. According to Zacks Investment Research, "Halozyme Therapeutics, Inc. is a therapeutically driven, development stage biopharmaceutical company dedicated to developing and commercializing recombinant human enzymes for the infertility, ophthalmology, and oncology communities. The company's broad product development portfolio, including expected near- and long-term product offerings, is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's initial products are being developed to offer safer and purer alternatives toexisting slaughterhouse derived extracts that carry risks of pathogen contamination, immunogenicity, and toxicity. The commercialization of Halozyme's highly versatile enzyme technology within proven markets will enable the company to positively impact the quality of medicine. " (4/25/2019) Has Halozyme Therapeutics been receiving favorable news coverage? News stories about HALO stock have been trending positive on Monday, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Halozyme Therapeutics earned a coverage optimism score of 2.3 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 9.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future. Who are some of Halozyme Therapeutics' key competitors? Some companies that are related to Halozyme Therapeutics include Qiagen (QGEN), BIO-TECHNE (TECH), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), argenx (ARGX), Spark Therapeutics (ONCE), Ablynx (ABLYF), China Biologic Products (CBPO), Allogene Therapeutics (ALLO), Repligen (RGEN), Acceleron Pharma (XLRN), Crispr Therapeutics (CRSP), Denali Therapeutics (DNLI), Iovance Biotherapeutics (IOVA) and Aerie Pharmaceuticals (AERI). What other stocks do shareholders of Halozyme Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Halozyme Therapeutics investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Micron Technology (MU), Allergan (AGN), Aegean Marine Petroleum Network (ANW) and Transocean (RIG). Who are Halozyme Therapeutics' key executives? Halozyme Therapeutics' management team includes the folowing people: Dr. Helen I. Torley, Pres, CEO & Director (Age 56)Ms. Laurie D. Stelzer, Sr. VP & CFO (Age 51)Mr. Harry J. Leonhardt, Sr. VP, Gen. Counsel & Corp. Sec. (Age 62)Dr. Dimitrios Chondros, Chief Medical Officer & Sr. VP (Age 54)Mr. Benjamin J. Hickey, Sr. VP & Chief Commercial Officer (Age 44) Who are Halozyme Therapeutics' major shareholders? Halozyme Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.05%), Iridian Asset Management LLC CT (4.82%), Pictet Asset Management Ltd. (2.69%), FMR LLC (1.85%), First Eagle Investment Management LLC (1.46%) and Artisan Partners Limited Partnership (1.41%). View Institutional Ownership Trends for Halozyme Therapeutics. Which institutional investors are selling Halozyme Therapeutics stock? HALO stock was sold by a variety of institutional investors in the last quarter, including Iridian Asset Management LLC CT, MERIAN GLOBAL INVESTORS UK Ltd, Man Group plc, Goldman Sachs Group Inc., SEI Investments Co, Morgan Stanley, Macquarie Group Ltd. and Dimensional Fund Advisors LP. View Insider Buying and Selling for Halozyme Therapeutics. Which institutional investors are buying Halozyme Therapeutics stock? HALO stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, William Blair Investment Management LLC, Candriam Luxembourg S.C.A., Federated Investors Inc. PA, Pictet Asset Management Ltd., Schonfeld Strategic Advisors LLC, Charles Schwab Investment Management Inc. and Jacobs Levy Equity Management Inc.. View Insider Buying and Selling for Halozyme Therapeutics. How do I buy shares of Halozyme Therapeutics? Shares of HALO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Halozyme Therapeutics' stock price today? One share of HALO stock can currently be purchased for approximately $15.61. How big of a company is Halozyme Therapeutics? Halozyme Therapeutics has a market capitalization of $2.27 billion and generates $151.86 million in revenue each year. The biopharmaceutical company earns $-80,330,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. Halozyme Therapeutics employs 281 workers across the globe. What is Halozyme Therapeutics' official website? The official website for Halozyme Therapeutics is http://www.halozyme.com. How can I contact Halozyme Therapeutics? Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-794-8889 or via email at [email protected] MarketBeat Community Rating for Halozyme Therapeutics (NASDAQ HALO)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 362 (Vote Outperform)Underperform Votes: 323 (Vote Underperform)Total Votes: 685MarketBeat's community ratings are surveys of what our community members think about Halozyme Therapeutics and other stocks. Vote "Outperform" if you believe HALO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HALO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/20/2019 by MarketBeat.com StaffFeatured Article: Marijuana Stocks Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.